Do Genes Really Determine Your Hobbies, Relationships, and Voting Habits?
By Catherine Bliss,
Zocalo Public Square
| 09. 25. 2018
Over the past 25 years, we’ve become surprisingly comfortable with the idea that genes play a large role in our lives. When DNA is in the mix, people assume that it is the primary cause of whatever human trait is being talked about. People may choose whether to pursue a hobby or a relationship based on test results—even though it means that they must dismiss the other information they have at their disposal. Judges have even used genetic tests to make sentencing decisions.
Even science has carried this idea to extremes. Genes, for example, are said to account for the difference between people who are perpetual cheaters and those in a lifelong committed relationship. Genes are said to be the reason why some people vote conservative while others vote liberal and why some don’t vote at all. Genes supposedly determine our ability to get through those last years of college, to keep ourselves out of credit card debt, or to invest in the stock market in order to plan for our retirement. And on and on.
If...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...